Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Nurix Therapeutics, Inc. (NRIX)

$23.38 -1.52% NASDAQ: NRIX · 15-min delayed
  • BRISBANE, California
  • Public · NASDAQ: NRIX
  • 357 employees
$1.5BMarket cap
$84.0MRevenue · FY2025
-$264.5MNet income
357Employees
NRIXNASDAQ
2020IPO

About Nurix Therapeutics, Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$84.0M
Net income
-$264.5M
Total assets
$688.1M
Market cap
$1.5B

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2026

Financial statements

Balance sheet

Total assets
$636.1M
Current assets
$554.4M
Total liabilities
$155.2M
Current liabilities
$92.2M
Shareholders’ equity
$480.9M

Statements via Polygon.io (SEC filings)

NASDAQ: NRIX
$23.38 -1.52%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$8.24 $24.69

52-week range

Market cap
$1.5B
Shares outstanding
64.8M
Open
Day range
Prev close
Volume
IPO date
Jul 24, 2020

Nurix Therapeutics, Inc. (NRIX) Stock Price

  • Reported a net loss of $264.5M in FY2025.
  • Revenue grew 182% from FY2021 to FY2025.
  • Trading 5% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Nurix Therapeutics, Inc..

Write a review
Newsroom

News about Nurix Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Nurix Therapeutics, Inc.: frequently asked questions

Is Nurix Therapeutics, Inc. an American company?

Nurix Therapeutics, Inc. is a US-based company headquartered in Brisbane, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Nurix Therapeutics, Inc. headquartered?

Nurix Therapeutics, Inc. is headquartered in Brisbane, California, United States.

Is Nurix Therapeutics, Inc. publicly traded?

Yes — Nurix Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol NRIX on the NASDAQ.

What does Nurix Therapeutics, Inc. do?

Nurix Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →